Subscribe to our Email Alerts
Menu
Home
About Us
Company Overview
Company Values
Board of Directors
Management
Corporate Directory
Products
DAYBUE™ (trofinetide)
Pipeline
Pipeline
Trofinetide
Rett Syndrome
Fragile X Syndrome
NNZ-2591
Phelan-McDermid Syndrome
Angelman Syndrome
Pitt Hopkins Syndrome
Prader-Willi Syndrome
Science
Science Behind Neuren's Products
Scientific Presentations
Publications
Investors
Investor Dashboard
Share Price Information
ASX Announcements
Annual and Interim Reports
Investor Presentations
Corporate Governance
Analyst Coverage
Shareholder Services
News & Media
Media
Contact
Contact Us
Email Alerts
Investors
Home
>
Investors
>
ASX Announcements
Investor Dashboard
Share Price Information
ASX Announcements
Annual and Interim Reports
Investor Presentations
Corporate Governance
Analyst Coverage
Shareholder Services
ASX Announcements
Filter by Year:
2024
2023
2022
2021
2020
2019
2018
2017
Older
Dec 12, 2019
2019 year-end update and 2020 outlook
Dec 03, 2019
Patent to 2034 granted in Europe for Neuren's NNZ-2591
Oct 31, 2019
Phase 3 trial of trofinetide in Rett syndrome commences
Oct 18, 2019
Neuren Corporate Presentation, October 2019
Oct 17, 2019
Appendix 4C - quarterly
Oct 16, 2019
FDA grants Orphan for both Phelan-McDermid and Pitt Hopkins
Oct 16, 2019
Pause in Trading
Oct 11, 2019
FDA grants Orphan Drug Designation for NNZ-2591 in Angelman
Sep 20, 2019
Neuren approaching key milestones in Q4 2019
Aug 28, 2019
Neuren advances pipeline for neurodevelopmental disorders
1
2
3
4
Next
